Skip to content

Study · Not a test of the peptide alone · 1996

2 results

Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli.

Peino R, Cordido F, Peñalva A, Alvarez CV, Dieguez C, Casanueva FF

The Journal of clinical endocrinology and metabolism1 Mar 1996Cited by 30 (Europe PMC)

PMID8772549 (opens in a new tab)DOI10.1210/jcem.81.3.8772549 (opens in a new tab)PepBankPUB-08772549
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

  1. 01HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome

    In normal subjects, acipimox pretreatment enhanced the GH response to GHRP‑6 compared with placebo pretreatment.

    In plain wordsIn healthy adults, the lipid drug acipimox increased the growth hormone rise after a GHRP‑6 test dose compared with placebo.

    Peptide
    GHRP-6
    Outcome
    IncreaseGH AUC after GHRP-6 with acipimox pretreatment
    Study

    n = 6

    Comparator
    Placebo pretreatment
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    GH AUC
    2034 micrograms per L/120 min
    placebo-GHRP-6
    GH AUC
    4827 micrograms per L/120 min
    acipimox-GHRP-6

    Source sentences

    Summary
    A similar enhancement was observed when the stimulus employed was GHRP-6 (n = 6; placebo-GHRP-6 AUC, 2034 +/- 295; acipimox-GHRP-6, 4827 +/- 703; P < 0.05).
    1 context sentence
    Summary · context
    To induce GH release, four stimuli acting through different mechanisms were used: pyridostigmine (120 mg, orally) at -60 min, GHRH (1 microgram/kg, iv) at 0 min, GH-releasing peptide (GHRP-6; His-D-Trp-Ala-Trp-D-Phe-Lys-NH2; 1 microgram/kg, iv) at 0 min, and finally, GHRH plus GHRP-6 at the same doses at 0 min.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  2. 02HumanNot a test of GHRP-6 aloneNon-randomized trialEfficacy outcome

    In normal subjects, acipimox pretreatment enhanced the GH response to GHRH plus GHRP‑6 compared with placebo pretreatment.

    In plain wordsIn healthy adults, acipimox increased the growth hormone rise after GHRH plus GHRP‑6 compared with placebo.

    Peptide
    GHRP-6
    Outcome
    IncreaseGH AUC after GHRH plus GHRP-6 with acipimox pretreatment
    Study

    n: not reported in source

    Comparator
    Placebo pretreatment
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    GH AUC
    2034 micrograms per L/120 min
    placebo-GHRH-GHRP-6
    GH AUC
    5809 micrograms per L/120 min
    acipimox-GHRH-GHRP-6

    Source sentences

    Summary
    Furthermore, even the most potent GH stimulus known to date, i.e. GHRH plus GHRP-6, was enhanced by the FFA suppression (placebo-GHRH-GHRP-6 AUC, 2034 +/- 277; acipimox-GHRH-GHRP-6, 5809 +/- 758; P < 0.05).
    1 context sentence
    Summary · context
    To induce GH release, four stimuli acting through different mechanisms were used: pyridostigmine (120 mg, orally) at -60 min, GHRH (1 microgram/kg, iv) at 0 min, GH-releasing peptide (GHRP-6; His-D-Trp-Ala-Trp-D-Phe-Lys-NH2; 1 microgram/kg, iv) at 0 min, and finally, GHRH plus GHRP-6 at the same doses at 0 min.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.